TerrAscend Corp. (TSND) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Valter Pinto
executiveAppreciate it, operator, and good afternoon to all of you. Glad to have you join TerrAscend's call on the financial results for our third quarter of 2026. Joining us this afternoon are Jason Wild, who serves as Executive Chairman; Ziad Ghanem, our President and Chief Executive Officer; and Eric Jackson, our Chief Financial Officer. Some of what we say today will be forward-looking, including remarks regarding the company's outlook—specifically the financial results we expect for the fourth quarter of 2026, along with the estimates and assumptions underlying those expectations. The discussion likewise addresses management's outlook on growth opportunities in both new and established markets—Ohio and New Jersey among them—along with the company's M&A approach, including the contribution anticipated from the Aunt Mary's acquisition. It further covers growth of cultivation capacity, the share repurchase program and priorities for allocating capital, plans concerning a possible uplisting to a U.S. exchange, and expectations about regulatory reform—rescheduling, possible tax relief, and hemp regulation—together with the benefits those changes might bring. All forward-looking statements made on today's call are subject to risks and uncertainties that may lead actual results to differ materially from what those statements project. Keep in mind that what actually happens, and when things occur, could differ substantially from what these forward-looking statements predict or suggest—and you shouldn't treat reported results as a signal of how the company will perform later. You can find more detail on these factors under the "Risk Factors" heading in the company's Form 10-K as filed with the Securities and Exchange Commission, along with other documents the company submits to the SEC periodically; those materials are accessible at sec.gov, on SEDAR+, and through the company's website at terrascend.com. Everything forward-looking said on this call reflects only today's date, and the company has no duty to update or revise any of it. Additionally, on this call the company might present financial measures under both GAAP and Non-GAAP. A reconciliation linking those Non-GAAP measures to the GAAP measures they most directly compare to appears in today's earnings press release and in our quarterly report on Form 10-Q covering the quarter that ended September 30, 2026, and you can locate it on the investor relations website of the company or through the SEC and SEDAR+ websites. At this point I want to bring in Mr. Jason Wild. Jason, the floor is yours.
Jason Wild
executiveGood afternoon, everyone, and thanks for being with us. In the third quarter, revenue, gross margin, EBITDA, and free cash flow each increased relative to the prior year. Revenue totaled $68.2 million, an increase of approximately 5% year-over-year. Gross margin for the quarter was 52.3%, compared with 52.1% in the third quarter of 2025. Adjusted EBITDA reached $17.5 million, versus $17 million in the third quarter of 2025. For the quarter, net cash generated by operations came to $8.8 million, and free cash flow was $6.1 million. That makes 17 quarters in a row with positive operating cash flow and 13 straight quarters of positive free cash flow, which works out to an operating cash flow yield of 17.7% and a free cash flow yield of 14% — impressive figures. These results show sustained strength across our vertically integrated core markets: New Jersey, Maryland, and Pennsylvania. In New Jersey, we closed the transaction with Aunt Mary's that we had announced earlier; it is our fifth dispensary in the state, brings in more than $10 million in annualized revenue, and is immediately accretive on both an EBITDA and a free cash flow basis. The acquisition of Aunt Mary's was finalized late in September, which meant its contribution to third-quarter revenue was only minor. In Maryland, we achieved revenue growth on both a year-over-year and sequential basis while keeping margins strong. Pennsylvania again stood out as one of our best-performing markets for the quarter, producing considerable year-over-year revenue growth along with margin expansion, fueled by a 12% rise in same-store retail sales and a 31% gain in wholesale revenue. On the balance sheet side, we finished the quarter holding $42.5 million in cash. The cash we keep generating, our solid balance sheet, and being able to draw on our term loan facility all leave us room to pursue more appealing opportunities. Our plan is to deploy that capital into acquisitions that boost earnings in markets where we already have scale and operational infrastructure, which lifts vertical revenue and adds operating leverage. Plenty of promising opportunities exist in the market right now, and we expect to share an update on them in the weeks ahead. Turning to regulatory reform, I'd like to give an update. As we've noted previously, we run the business regardless of regulatory reform, and if reform succeeds, that's upside. This year's move of state-licensed medical cannabis to Schedule III is still a huge turning point for the sector. The biggest near-term effect comes from dropping the 280E tax burden on medical cannabis, and that should meaningfully boost profitability and cash flow, make our balance sheet stronger, and bring down our cost of capital as time goes on. We could also see retroactive tax relief, a sizable upside possibility that in our view market valuations have not yet priced in. Our reported results still include the 280E impact, and we expect further updates in the fourth quarter. As for rescheduling cannabis more broadly, the DEA administrative proceedings are ongoing. Although the process is still underway and both timing and result are unclear, everything we have observed so far leaves our view of the ultimate outcome unchanged. In connection with the medical rescheduling process, the DEA has been carrying out on-site inspections at our facilities. We have finished many inspections, and the process is moving forward. We are also seeing continued progress on other important fronts. Enforcement against unregulated hemp products keeps building ahead of the intoxicating hemp ban set to take effect on December 11. As we have noted previously, the intoxicating hemp market is arguably the biggest competitor our industry faces, and we look forward to serving those consumers as they come back to the regulated market. Talks with the big U.S. exchanges are still ongoing, and we keep doing the work required to get ready for a possible listing. On the M&A side, we're concentrated on acquisitions that are disciplined and accretive. As I noted, we completed the Aunt Mary's deal in New Jersey back in September. Today's conditions keep throwing up opportunities—distressed assets among them—in our core markets as well as in a few chosen new ones. We've stayed patient and disciplined throughout those discussions, and I'm eager to bring you an update in the next few weeks. On the subject of our repurchase program, in August we refreshed and restored the authorization covering up to whichever is smaller — 10 million common shares or $10 million of common shares — running from August 24, 2026 through August 23, 2027. Our open trading window during the quarter totaled 35 trading days. Across that stretch, we bought back 1,013,000 shares. We'll keep executing the buyback while weighing our other capital allocation priorities, among them growth investments, capital expenditures, and selective M&A. With that, I'll hand the call over to Ziad for an update across our key markets. Z?
Ziad Ghanem
executiveThanks, Jason. Now I’ll take you through how we did in each of our main markets for the quarter, starting with New Jersey. Even with tougher retail competition and price compression in the state, New Jersey revenue was up slightly compared with a year earlier. TerrAscend held on to a leading position in New Jersey, picking up both sales and share across our core product categories, which speaks to the strength of our brands and the quality of what we sell. In the quarter, we completed the Aunt Mary’s transaction, which brings our fifth dispensary in the state, and we’re glad to have the Aunt Mary’s team join the TerrAscend family. Each new store we open in New Jersey boosts usage at the facility we already run, which allows us to get more out of our assets through better economies of scale and by selling more of our products vertically. Our goal is to keep expanding our footprint in the state by way of accretive acquisitions. We're also increasing capacity at our cultivation site in Boonton. This quarter we completed a major phase on budget, and we're planning conservatively for about 20% additional greenhouse yield. That extra supply will serve our expanding retail base and our entire brand portfolio, ranging from our growing premium solventless lineup to value-oriented flower sold under our Legend brand. In flower, we came in third with 8.3% share. On the vape side, we continue to gain share, and Legend vapes are still the top-selling vape cartridge brand, holding 12.1% across 215 brands. Looking ahead, we remain focused on disciplined growth in New Jersey, and that includes continuing to evaluate expanding capacity at our Boonton cultivation facility as well as additional retail licenses, all as part of our long-term aim of maximizing our footprint in the state. Over in Maryland, the business had a solid quarter. Revenue was up year-over-year, and gross margins were roughly flat. Our Maryland operation is running at an annualized revenue level of about $75 million, with gross margins in the high 50s. We started in Maryland back in 2021 by buying a small grow operation that brought in almost no revenue. Then, in the first half of 2023, right before adult-use sales began, we picked up four dispensaries. The fact that we've gone from essentially no revenue to the results we're now delivering quarter after quarter demonstrates how effective our vertically integrated operating model is in that state, thanks to disciplined execution in both cultivation and retail. On the brand side, we're seeing momentum throughout the portfolio. We picked up market share this quarter across every category, including flower, pre-rolls, and vapes. On top of that, new product launches have fueled Valhalla's growth over the past two quarters. Our new Kind Tree and Tyson 2.0 edibles added close to another point of market share during the quarter. Going forward, we're still concentrating on becoming more efficient, broadening our manufacturing presence, and fine-tuning cultivation and retail operations in Maryland. Turning to Pennsylvania, the state was again among our best-performing markets this quarter. Revenue climbed 16.8% versus the prior year, driven by a 12% increase in same-store sales and a 31% rise in wholesale revenue, while gross margins expanded 800 basis points. At five of our six Apothecarium locations, we placed within the state's top 15 stores. That quarter was our fourth straight with sequential revenue growth, and it made Pennsylvania our fastest-growing core market in the period. On the brand side, much like Maryland, we picked up market share during the quarter across every category. We were also one of the first suppliers to launch 100 milligram medical troches, which have quickly turned into one of our best-selling SKUs. In sublinguals we likewise grew share, reaching 21%, and five of the market's top 15 SKUs are tinctures under our Ilera brand. Pennsylvania stays among our most attractive opportunities for growth both near term and long term. Our big cultivation and manufacturing site is now completely built out and operating at the highest utilization we've seen in years. Finished flower production is 68% higher than a year ago, and we still have room to spare for future medical and adult-use demand. Turning to Ohio, sales increased by a double-digit percentage compared with last year, as we won back customers who came back to the regulated market after the state outlawed intoxicating hemp products. In that state, our strategy is to establish a scaled, high-quality retail presence through disciplined, accretive acquisitions, and we are actively evaluating a number of opportunities. Overall, I'm very pleased with our third-quarter performance. Across our primary territories of New Jersey, Maryland, and Pennsylvania, we delivered strong operational results. During the quarter, we introduced a considerable variety of new items throughout our markets. Our drive for efficiency, rigorous expense control, and vertical integration continues to underpin steady financial results. Robust free cash flow stems from our premium brand lineup, our dedication to product innovation, and execution that ranks among the best. Since no significant debt matures before 2028, our balance sheet remains a major advantage and provides us with considerable financial flexibility. Given our strengthening fundamentals, prudent M&A approach, ongoing free cash flow generation, and top-tier sponsorship, I am confident in our capacity to deliver long-term shareholder value in 2026 and beyond. With that, I'll pass things over to Eric, who'll take us through the financial results in greater detail. Eric?
Eric Jackson
executiveThanks, Ziad. Good afternoon, everyone. The results I'll be walking through today have been filed with SEDAR+ as well as the SEC, and every figure is in USD. Net revenue in the third quarter of 2026 came to $68.2 million, up against $65.1 million in the third quarter of 2025 — roughly 5% growth year over year. Retail revenue rose on a year-over-year basis, while wholesale revenue stayed essentially flat. Gross margin in the third quarter was 52.3% versus 52.1% in the third quarter of 2025, a return to more normalized levels after an exceptionally strong second quarter. G&A expenses in the third quarter were $24 million, or 35.2% of revenue, against $21.3 million, or 32.8% of revenue, in the third quarter of 2025. That increase came mainly from one-time transaction costs tied to our convertible debenture financing and acquisition-related professional fees, both of which are excluded from adjusted EBITDA. Net loss from continuing operations in the third quarter was $5.5 million, versus a net loss from continuing operations of $9.9 million in the third quarter of 2025. The improvement mainly reflects a $4.8 million gain on the fair value of derivative liabilities compared with a $700,000 loss in the prior year period, partly offset by lower income from operations and a higher provision for income taxes. Adjusted EBITDA in the third quarter was $17.5 million, or 25.6% of revenue, compared with $17 million, or 26.1% of revenue, in the third quarter of 2025. That year-over-year increase reflects gross profit growth, partly offset by higher operating expenses. Turning to the balance sheet and cash flow, cash and cash equivalents stood at $42.5 million as of September 30th, 2026. Cash flow from operations in the third quarter was $8.8 million, marking our 17th consecutive quarter of positive operating cash flow. Capital expenditures in the third quarter were $2.7 million, mainly tied to ongoing cultivation and facility optimization projects. Free cash flow in the third quarter was $6.1 million, marking our 13th consecutive quarter of positive free cash flow. During the quarter, we kept allocating capital in a disciplined manner while maintaining a strong liquidity position. We expect mid-single-digit year-over-year revenue growth in Q4 2026; we also expect consistently strong gross margin performance. In summary, our third quarter results reflect continued operational momentum, improving profitability, and consistent cash flow generation, supported by disciplined cost management and a strong operating platform. I look forward to sharing continued progress in the quarters ahead. That concludes our prepared remarks. I'll now turn it back to the operator for questions.
Frederico Gomes
analystYes, hello and thanks for the chance to ask a few things. Great quarter — congratulations. I want to start with Pennsylvania. Same-store sales growth there is clearly very strong and impressive, and the wholesale side grew too. Could you expand a bit on what precisely is behind that? And regarding capacity utilization and the margin improvement you saw, how much additional volume can that facility handle, and what upside to margins might there be if you intend to increase the ramp a little further? Thank you.
Ziad Ghanem
executiveYes, thank you, Fred. Look, the work we've done in Pennsylvania is something we're extremely proud of, on both revenue growth and gross margin. Looking at both sequential and year-over-year figures, our revenue has grown by double digits on a year-over-year basis—roughly 11.6%—and gross margin has improved as well. No single magic bullet is driving this. We consistently point to the mix of several differentiators we bring. It begins with quality, the strain selections, and the brand portfolio we hold. The consumer has truly been the judge here, right? Customers keep coming back for more and keep pushing our verticality higher. On fresh supply—most of our inventory, all of it really, doesn't last more than 60 days from harvest to consumption. That freshness is helping; we launched a new partnership with Tyson 2.0. Demand outstripped supply — we sold out. Our reach-out efforts, the campaigns run by our marketing group, and the way our retail locations serve customers have truly created that edge for us. In Pennsylvania we've posted that kind of result across several quarters. Another distinctive thing about Pennsylvania: the statewide average retail price has declined. Ours has risen, and that comes from every factor I just listed. On capacity, we often note that Pennsylvania is our largest site — equal in size to all our other facilities put together. We've expanded capacity further. We're nearly at 50% capacity, so we're fairly at ease with no CapEx growth and no CapEx requirement, since we can scale up to meet the organic rise we're seeing in the medical program. We're also positioned and ready for adult use, which is looking stronger and stronger given the shift we've witnessed with the political trifecta that occurred in Pennsylvania. Capacity isn't an issue. We're eager to see more demand arrive, fueled by organic growth, by adult-use potential, and by the hemp loophole that will close in December.
Jason Wild
executiveLet me just jump in here, because Ziad actually undersold us a bit. He mentioned Pennsylvania business was up 11.6%. That figure covered retail only, on the same-store base, roughly 12% same-store sales growth. Wholesale, as we said, rose 31% versus a year ago, and combined that came to 16 and change percent total growth in Pennsylvania.
Ziad Ghanem
executiveHow did I do that? Thanks, Jason.
Jason Wild
executiveI figured that slipped past you.
Frederico Gomes
analystAll right, thanks for that, guys. One more question, this time about Pennsylvania. You brought up the possibility of adult use. Clearly, you've discussed M&A previously — New Jersey, Ohio — but how about Pennsylvania? You're seeing opportunities there. Does it perhaps make you more bullish about pursuing M&A, maybe additional dispensaries, since the adult-use outlook has possibly gotten better for next year?
Ziad Ghanem
executiveYeah, look, Fred, when it comes to M&A, we've demonstrated that we possess the capability and the internal muscles to buy operating businesses, integrate them effectively, realize the synergy, and generate growth from them. We've stated that on the M&A front, we aim to go deeper in the states where we already operate, much like what we did in New Jersey, and then we seek the right opportunity in any state where we are present; that means Pennsylvania, that means Ohio. Beyond that, though, we're examining new states, be it through a new application or states that have only recently transitioned to adult use, or that remain medical. So we're fond of Florida, we're fond of Missouri, we're fond of Ohio. So we're holding plenty of conversations. The thing we hold ourselves accountable to is remaining disciplined. To strike the right deal at the right price that is immediately accretive to our EBITDA and to our cash flow; we took a swing and we missed in Pennsylvania, so we keep hunting for opportunities that would let us leverage our facility, grow our business, and keep enhancing our gross margin. We're convinced — given the opportunities we're seeing, the conversations we're having, and the stage those conversations are at — that now, after building efficiency and having delivered some of the strongest margin in the industry regardless of size, our company will look completely different in 2027, and we can't wait to share that news.
Jason Wild
executiveOne more point on that: Ziad said we swung and missed in Pennsylvania, and I want to clarify that a bit. We served as the stalking horse bid for a multi-store acquisition that ultimately went to another party. I believe we received $1 million, or $1 million and change, for acting as the stalking horse bid, but I think it also just shows our discipline. The final price came in substantially above what we originally bid, and we walked away. That said, I would note there are plenty of other deals on the table, and our confidence keeps growing that we will deliver on some significant transactions going forward.
Frederico Gomes
analystMany thanks. This is Nikki once more.
Kenric Tyghe
analystThank you, and good evening. Ziad, in the previous quarter your team implemented what amounted to a reset across New Jersey. I believe we're clearly seeing the benefits of that now this quarter. Could you remind us what makes your footprint distinctive, considering how cultivation-focused you are in New Jersey and Pennsylvania alike, and how valuable those differentiators could turn out to be as we watch this market develop — the hemp ban, sales moving back toward the legal channel — and how strongly positioned you are to capture that, both in absolute and relative terms against some of your competitors in these key markets?
Ziad Ghanem
executiveYeah. Hey, Kenric. Here's how I'd put it: we apply one consistent playbook in each state where we do business. Between the brands we carry — the value label alongside the premium one — plus how consumers are responding, the loyalty we're building and the momentum showing up in retail and wholesale alike, we're confident this is the right approach to produce top-tier financial results, and we've already talked that up. On hemp, there's no need for guesswork — we can simply point to a small case study already running in Ohio. We've spoken with numerous operators across Ohio, and they're reporting revenue gains in the range of 20% to 30%. In the single Ohio store we operate, we're seeing a lift in the double digits. Obviously, it stands to reason that these are items that have delivered an enormous positive impact on people's lives. Customers have gotten off synthetic medications — sleep aids, anxiety drugs, painkillers — and reclaimed their lives by taking a five milligram gummy in the evening. Once those shoppers can no longer reach illicit sellers, smoke shops, or gas stations, they'll need somewhere else to go—and our industry, both us and our rivals, stands prepared to bring those customers in with superior goods, a superior experience, and tested, safe products. That merge of two sectors of apparently comparable scale could ultimately double the size of our industry.
Kenric Tyghe
analystThanks, Ziad — that helps. Maybe also on New Jersey, could you remind us of the pace at which new stores are opening? Are you finding that it's slowing as the market matures, and what does that mean for your growth algorithm in the state? I mean, we're certainly past what was that big hump, I think, and openings perhaps look more normal now, but I'd love your view on new doors, the cadence of new doors, and what that tells us about your wholesale ramp or continued ramp in wholesale.
Ziad Ghanem
executiveYeah, new doors are opening in New Jersey. How much each company we see affects our own stores depends on where those stores sit geographically. Early on, when we went from 17 stores to 100, 150 stores, plenty came in around our stores, and we saw that hit at retail. Since then, we've managed to see same-store volume increase, and we saw the wholesale benefit as more stores opened in different trade areas. But recently — and this is something I'm super proud of with our team — our biggest store in our retail network in Phillipsburg, the store that does north of $30 million, had a store open just a couple of hundred yards away. In April, the soft launch happened. In May, the full opening took place, the grand opening took place. Every month since, our store has seen no impact on its revenue, and that isn't by coincidence. That comes from a targeted approach and targeted pricing that we do store by store, and from the quality I talked about that keeps our consumers showing their loyalty. From an overall perspective, yes — the more stores open, the more penetration we get from a wholesale perspective, and we continue to manage our capacity between improved verticality in our stores and then adding new doors in the state.
Kenric Tyghe
analystThanks.
Jason Wild
executiveThanks. As we wrap up, we like to say that our aim isn't to become the largest player in cannabis. What we aim for is excellence; over the past several quarters, we've delivered profitability margins among the very best, even alongside businesses four to five times larger than ours. Given what we're seeing in the market right now, we're really eager to show you how this business will look in 2027 and beyond. Thanks.
Operator
operatorThank you. That brings us to the end of today's conference call, ladies and gentlemen. We appreciate everyone for joining. You may disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete TerrAscend Corp. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to TerrAscend Corp. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in TerrAscend Corp. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.